A detailed history of Tower Research Capital LLC (Trc) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 9,568 shares of FDMT stock, worth $103,621. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,568
Previous 982 874.34%
Holding current value
$103,621
Previous $31,000 545.16%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$20.93 - $30.01 $179,704 - $257,665
8,586 Added 874.34%
9,568 $200,000
Q1 2024

May 15, 2024

SELL
$17.03 - $35.87 $147,190 - $310,024
-8,643 Reduced 89.8%
982 $31,000
Q4 2023

Feb 13, 2024

BUY
$9.76 - $21.25 $83,018 - $180,752
8,506 Added 760.14%
9,625 $195,000
Q3 2023

Nov 14, 2023

SELL
$12.64 - $19.76 $24,180 - $37,800
-1,913 Reduced 63.09%
1,119 $14,000
Q2 2023

Aug 14, 2023

SELL
$15.16 - $23.26 $80,863 - $124,068
-5,334 Reduced 63.76%
3,032 $54,000
Q1 2023

May 09, 2023

BUY
$15.45 - $23.19 $71,657 - $107,555
4,638 Added 124.41%
8,366 $144,000
Q4 2022

Feb 10, 2023

SELL
$6.85 - $25.46 $4,610 - $17,134
-673 Reduced 15.29%
3,728 $83,000
Q3 2022

Nov 10, 2022

SELL
$6.96 - $11.48 $17,413 - $28,722
-2,502 Reduced 36.25%
4,401 $35,000
Q2 2022

Aug 15, 2022

BUY
$5.68 - $15.99 $29,087 - $81,884
5,121 Added 287.37%
6,903 $48,000
Q1 2022

May 12, 2022

SELL
$13.16 - $22.64 $25,359 - $43,627
-1,927 Reduced 51.95%
1,782 $27,000
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $11,931 - $20,093
610 Added 19.68%
3,709 $81,000
Q3 2021

Nov 15, 2021

BUY
$22.73 - $36.04 $48,392 - $76,729
2,129 Added 219.48%
3,099 $84,000
Q2 2021

Aug 16, 2021

BUY
$22.2 - $42.29 $8,125 - $15,478
366 Added 60.6%
970 $23,000
Q1 2021

May 17, 2021

BUY
$35.94 - $52.67 $21,707 - $31,812
604 New
604 $26,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $351M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.